Loading…
Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia
We hypothesized that concomitant pharmacological inhibition of the endothelin and adenosine pathway is safe and improves exercise performance in hypoxic humans, via a mechanism that does not involve augmentation of blood oxygenation. To test this hypothesis, we established safety and drug interactio...
Saved in:
Published in: | Clinical pharmacology and therapeutics 2018-05, Vol.103 (5), p.888-898 |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c4750-a54ff1690305fa54183b1051f33524663b6f729754c89d34fbccd007b998c0a03 |
---|---|
cites | cdi_FETCH-LOGICAL-c4750-a54ff1690305fa54183b1051f33524663b6f729754c89d34fbccd007b998c0a03 |
container_end_page | 898 |
container_issue | 5 |
container_start_page | 888 |
container_title | Clinical pharmacology and therapeutics |
container_volume | 103 |
creator | Schroeder, Thies Piantadosi, Claude A. Natoli, Michael J. Autmizguine, Julie Cohen‐Wolkowieczs, Michael Hamilton, Karyn L. Bell, Christopher Klawitter, Jelena Christians, Uwe Irwin, David C. Noveck, Robert J. |
description | We hypothesized that concomitant pharmacological inhibition of the endothelin and adenosine pathway is safe and improves exercise performance in hypoxic humans, via a mechanism that does not involve augmentation of blood oxygenation. To test this hypothesis, we established safety and drug interactions for aminophylline (500 mg) plus ambrisentan (5 mg) in normoxic volunteers. Subsequently, a placebo‐controlled study was employed to test the combination in healthy resting and exercising volunteers at simulated altitude (4,267 m). No serious adverse events occurred. Drug interaction was minimal or absent. Aminophylline alleviated hypoxia‐induced headaches. Aminophylline, ambrisentan, and their combination all significantly (P < 0.05 vs. placebo) improved submaximal hypoxic exercise performance (19.5, 20.6, and 19.1% >placebo). Single‐dose ambrisentan increased blood oxygenation in resting, hypoxic subjects. We conclude that combined aminophylline and ambrisentan offer promise to safely increase exercise capacity in hypoxemic humans without relying on increasing blood oxygen availability. |
doi_str_mv | 10.1002/cpt.860 |
format | article |
fullrecord | <record><control><sourceid>wiley_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5947522</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CPT860</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4750-a54ff1690305fa54183b1051f33524663b6f729754c89d34fbccd007b998c0a03</originalsourceid><addsrcrecordid>eNp1kN1LwzAUxYMobk7xP5C--SCd-Wja5EUYZTph4MD5HNI02SJtU9L60f_ezKnog0-Xwz33dw8HgHMEpwhCfK3afspSeADGiBIcp5TQQzCGEPKYY5KOwEnXPQeZcMaOwQgzRjOUZGOwfpRG90MkmzKa-43b6MaqaOVdq31vdRc5E-WuLmyjy2hW28a126Gqgvw8mdWFt51uetlEtokWQ-verTwFR0ZWnT77mhPwdDtf54t4-XB3n8-WsUoyCmNJE2NQyiGB1ASBGCkQpMgQQnGSpqRITYZ5RhPFeEkSUyhVQpgVnDMFJSQTcLPnti9FrUsVcnhZidbbWvpBOGnF301jt2LjXgXlIQDGAXC5Byjvus5r83OLoNgVK0KxIhQbnBe_X_34vpsMhqu94c1WeviPI_LVeof7AKbbgnA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Schroeder, Thies ; Piantadosi, Claude A. ; Natoli, Michael J. ; Autmizguine, Julie ; Cohen‐Wolkowieczs, Michael ; Hamilton, Karyn L. ; Bell, Christopher ; Klawitter, Jelena ; Christians, Uwe ; Irwin, David C. ; Noveck, Robert J.</creator><creatorcontrib>Schroeder, Thies ; Piantadosi, Claude A. ; Natoli, Michael J. ; Autmizguine, Julie ; Cohen‐Wolkowieczs, Michael ; Hamilton, Karyn L. ; Bell, Christopher ; Klawitter, Jelena ; Christians, Uwe ; Irwin, David C. ; Noveck, Robert J.</creatorcontrib><description>We hypothesized that concomitant pharmacological inhibition of the endothelin and adenosine pathway is safe and improves exercise performance in hypoxic humans, via a mechanism that does not involve augmentation of blood oxygenation. To test this hypothesis, we established safety and drug interactions for aminophylline (500 mg) plus ambrisentan (5 mg) in normoxic volunteers. Subsequently, a placebo‐controlled study was employed to test the combination in healthy resting and exercising volunteers at simulated altitude (4,267 m). No serious adverse events occurred. Drug interaction was minimal or absent. Aminophylline alleviated hypoxia‐induced headaches. Aminophylline, ambrisentan, and their combination all significantly (P < 0.05 vs. placebo) improved submaximal hypoxic exercise performance (19.5, 20.6, and 19.1% >placebo). Single‐dose ambrisentan increased blood oxygenation in resting, hypoxic subjects. We conclude that combined aminophylline and ambrisentan offer promise to safely increase exercise capacity in hypoxemic humans without relying on increasing blood oxygen availability.</description><identifier>ISSN: 0009-9236</identifier><identifier>EISSN: 1532-6535</identifier><identifier>DOI: 10.1002/cpt.860</identifier><identifier>PMID: 28857147</identifier><language>eng</language><publisher>United States: John Wiley and Sons Inc</publisher><subject>Adenosine - metabolism ; Adolescent ; Adult ; Altitude ; Aminophylline - adverse effects ; Aminophylline - therapeutic use ; Double-Blind Method ; Drug Therapy, Combination - adverse effects ; Endothelins - drug effects ; Endothelins - metabolism ; Exercise - physiology ; Female ; Humans ; Hypoxia - drug therapy ; Hypoxia - metabolism ; Male ; Middle Aged ; Phenylpropionates - adverse effects ; Phenylpropionates - therapeutic use ; Pyridazines - adverse effects ; Pyridazines - therapeutic use ; Signal Transduction - drug effects ; Young Adult</subject><ispartof>Clinical pharmacology and therapeutics, 2018-05, Vol.103 (5), p.888-898</ispartof><rights>2017 The Authors Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics</rights><rights>2017 The Authors Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4750-a54ff1690305fa54183b1051f33524663b6f729754c89d34fbccd007b998c0a03</citedby><cites>FETCH-LOGICAL-c4750-a54ff1690305fa54183b1051f33524663b6f729754c89d34fbccd007b998c0a03</cites><orcidid>0000-0002-6320-8824 ; 0000-0003-1893-6141</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28857147$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schroeder, Thies</creatorcontrib><creatorcontrib>Piantadosi, Claude A.</creatorcontrib><creatorcontrib>Natoli, Michael J.</creatorcontrib><creatorcontrib>Autmizguine, Julie</creatorcontrib><creatorcontrib>Cohen‐Wolkowieczs, Michael</creatorcontrib><creatorcontrib>Hamilton, Karyn L.</creatorcontrib><creatorcontrib>Bell, Christopher</creatorcontrib><creatorcontrib>Klawitter, Jelena</creatorcontrib><creatorcontrib>Christians, Uwe</creatorcontrib><creatorcontrib>Irwin, David C.</creatorcontrib><creatorcontrib>Noveck, Robert J.</creatorcontrib><title>Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia</title><title>Clinical pharmacology and therapeutics</title><addtitle>Clin Pharmacol Ther</addtitle><description>We hypothesized that concomitant pharmacological inhibition of the endothelin and adenosine pathway is safe and improves exercise performance in hypoxic humans, via a mechanism that does not involve augmentation of blood oxygenation. To test this hypothesis, we established safety and drug interactions for aminophylline (500 mg) plus ambrisentan (5 mg) in normoxic volunteers. Subsequently, a placebo‐controlled study was employed to test the combination in healthy resting and exercising volunteers at simulated altitude (4,267 m). No serious adverse events occurred. Drug interaction was minimal or absent. Aminophylline alleviated hypoxia‐induced headaches. Aminophylline, ambrisentan, and their combination all significantly (P < 0.05 vs. placebo) improved submaximal hypoxic exercise performance (19.5, 20.6, and 19.1% >placebo). Single‐dose ambrisentan increased blood oxygenation in resting, hypoxic subjects. We conclude that combined aminophylline and ambrisentan offer promise to safely increase exercise capacity in hypoxemic humans without relying on increasing blood oxygen availability.</description><subject>Adenosine - metabolism</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Altitude</subject><subject>Aminophylline - adverse effects</subject><subject>Aminophylline - therapeutic use</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination - adverse effects</subject><subject>Endothelins - drug effects</subject><subject>Endothelins - metabolism</subject><subject>Exercise - physiology</subject><subject>Female</subject><subject>Humans</subject><subject>Hypoxia - drug therapy</subject><subject>Hypoxia - metabolism</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Phenylpropionates - adverse effects</subject><subject>Phenylpropionates - therapeutic use</subject><subject>Pyridazines - adverse effects</subject><subject>Pyridazines - therapeutic use</subject><subject>Signal Transduction - drug effects</subject><subject>Young Adult</subject><issn>0009-9236</issn><issn>1532-6535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNp1kN1LwzAUxYMobk7xP5C--SCd-Wja5EUYZTph4MD5HNI02SJtU9L60f_ezKnog0-Xwz33dw8HgHMEpwhCfK3afspSeADGiBIcp5TQQzCGEPKYY5KOwEnXPQeZcMaOwQgzRjOUZGOwfpRG90MkmzKa-43b6MaqaOVdq31vdRc5E-WuLmyjy2hW28a126Gqgvw8mdWFt51uetlEtokWQ-verTwFR0ZWnT77mhPwdDtf54t4-XB3n8-WsUoyCmNJE2NQyiGB1ASBGCkQpMgQQnGSpqRITYZ5RhPFeEkSUyhVQpgVnDMFJSQTcLPnti9FrUsVcnhZidbbWvpBOGnF301jt2LjXgXlIQDGAXC5Byjvus5r83OLoNgVK0KxIhQbnBe_X_34vpsMhqu94c1WeviPI_LVeof7AKbbgnA</recordid><startdate>201805</startdate><enddate>201805</enddate><creator>Schroeder, Thies</creator><creator>Piantadosi, Claude A.</creator><creator>Natoli, Michael J.</creator><creator>Autmizguine, Julie</creator><creator>Cohen‐Wolkowieczs, Michael</creator><creator>Hamilton, Karyn L.</creator><creator>Bell, Christopher</creator><creator>Klawitter, Jelena</creator><creator>Christians, Uwe</creator><creator>Irwin, David C.</creator><creator>Noveck, Robert J.</creator><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6320-8824</orcidid><orcidid>https://orcid.org/0000-0003-1893-6141</orcidid></search><sort><creationdate>201805</creationdate><title>Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia</title><author>Schroeder, Thies ; Piantadosi, Claude A. ; Natoli, Michael J. ; Autmizguine, Julie ; Cohen‐Wolkowieczs, Michael ; Hamilton, Karyn L. ; Bell, Christopher ; Klawitter, Jelena ; Christians, Uwe ; Irwin, David C. ; Noveck, Robert J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4750-a54ff1690305fa54183b1051f33524663b6f729754c89d34fbccd007b998c0a03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adenosine - metabolism</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Altitude</topic><topic>Aminophylline - adverse effects</topic><topic>Aminophylline - therapeutic use</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination - adverse effects</topic><topic>Endothelins - drug effects</topic><topic>Endothelins - metabolism</topic><topic>Exercise - physiology</topic><topic>Female</topic><topic>Humans</topic><topic>Hypoxia - drug therapy</topic><topic>Hypoxia - metabolism</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Phenylpropionates - adverse effects</topic><topic>Phenylpropionates - therapeutic use</topic><topic>Pyridazines - adverse effects</topic><topic>Pyridazines - therapeutic use</topic><topic>Signal Transduction - drug effects</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schroeder, Thies</creatorcontrib><creatorcontrib>Piantadosi, Claude A.</creatorcontrib><creatorcontrib>Natoli, Michael J.</creatorcontrib><creatorcontrib>Autmizguine, Julie</creatorcontrib><creatorcontrib>Cohen‐Wolkowieczs, Michael</creatorcontrib><creatorcontrib>Hamilton, Karyn L.</creatorcontrib><creatorcontrib>Bell, Christopher</creatorcontrib><creatorcontrib>Klawitter, Jelena</creatorcontrib><creatorcontrib>Christians, Uwe</creatorcontrib><creatorcontrib>Irwin, David C.</creatorcontrib><creatorcontrib>Noveck, Robert J.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Online Library Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schroeder, Thies</au><au>Piantadosi, Claude A.</au><au>Natoli, Michael J.</au><au>Autmizguine, Julie</au><au>Cohen‐Wolkowieczs, Michael</au><au>Hamilton, Karyn L.</au><au>Bell, Christopher</au><au>Klawitter, Jelena</au><au>Christians, Uwe</au><au>Irwin, David C.</au><au>Noveck, Robert J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia</atitle><jtitle>Clinical pharmacology and therapeutics</jtitle><addtitle>Clin Pharmacol Ther</addtitle><date>2018-05</date><risdate>2018</risdate><volume>103</volume><issue>5</issue><spage>888</spage><epage>898</epage><pages>888-898</pages><issn>0009-9236</issn><eissn>1532-6535</eissn><abstract>We hypothesized that concomitant pharmacological inhibition of the endothelin and adenosine pathway is safe and improves exercise performance in hypoxic humans, via a mechanism that does not involve augmentation of blood oxygenation. To test this hypothesis, we established safety and drug interactions for aminophylline (500 mg) plus ambrisentan (5 mg) in normoxic volunteers. Subsequently, a placebo‐controlled study was employed to test the combination in healthy resting and exercising volunteers at simulated altitude (4,267 m). No serious adverse events occurred. Drug interaction was minimal or absent. Aminophylline alleviated hypoxia‐induced headaches. Aminophylline, ambrisentan, and their combination all significantly (P < 0.05 vs. placebo) improved submaximal hypoxic exercise performance (19.5, 20.6, and 19.1% >placebo). Single‐dose ambrisentan increased blood oxygenation in resting, hypoxic subjects. We conclude that combined aminophylline and ambrisentan offer promise to safely increase exercise capacity in hypoxemic humans without relying on increasing blood oxygen availability.</abstract><cop>United States</cop><pub>John Wiley and Sons Inc</pub><pmid>28857147</pmid><doi>10.1002/cpt.860</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-6320-8824</orcidid><orcidid>https://orcid.org/0000-0003-1893-6141</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0009-9236 |
ispartof | Clinical pharmacology and therapeutics, 2018-05, Vol.103 (5), p.888-898 |
issn | 0009-9236 1532-6535 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5947522 |
source | Wiley-Blackwell Read & Publish Collection |
subjects | Adenosine - metabolism Adolescent Adult Altitude Aminophylline - adverse effects Aminophylline - therapeutic use Double-Blind Method Drug Therapy, Combination - adverse effects Endothelins - drug effects Endothelins - metabolism Exercise - physiology Female Humans Hypoxia - drug therapy Hypoxia - metabolism Male Middle Aged Phenylpropionates - adverse effects Phenylpropionates - therapeutic use Pyridazines - adverse effects Pyridazines - therapeutic use Signal Transduction - drug effects Young Adult |
title | Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T06%3A17%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20Ergogenic%20Properties%20of%20Combined%20Aminophylline%20and%20Ambrisentan%20in%20Hypoxia&rft.jtitle=Clinical%20pharmacology%20and%20therapeutics&rft.au=Schroeder,%20Thies&rft.date=2018-05&rft.volume=103&rft.issue=5&rft.spage=888&rft.epage=898&rft.pages=888-898&rft.issn=0009-9236&rft.eissn=1532-6535&rft_id=info:doi/10.1002/cpt.860&rft_dat=%3Cwiley_pubme%3ECPT860%3C/wiley_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4750-a54ff1690305fa54183b1051f33524663b6f729754c89d34fbccd007b998c0a03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/28857147&rfr_iscdi=true |